Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III Melanoma
Clinical trial NCT01605162 · TERMINATED
Trial details
- NCT number
- NCT01605162
- Sponsor
- Eisai Inc.
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2012-05-01
- Primary completion
- 2014-02-01
- Enrollment
- 8
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.